Reports Q1 revenue $7.6M, consensus $6.99M. “Our ClearPoint Neuro team enjoyed the best operating performance in our company’s history, with contributions coming from all four of our growth pillars,” commented Joe Burnett, CEO at ClearPoint Neuro. “Overall, the company achieved record revenue of $7.6M or 41% growth, led by 61% growth in biologics and drug delivery revenue, and 255% growth in capital sales and service, which were also both new records. We were thrilled to see not only over 60% growth in the core biologics business, but to see many of our partners progress from a regulatory standpoint including the first neuro gene therapy BLA ever submitted to the FDA, and first patient enrolled in multiple partner IDE trials since the start of the year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLPT:
- ClearPoint Neuro Engages Stakeholders with Updated Presentation
- ClearPoint Neuro announces FDA clearance of Prism Bone Anchor Accessory
- ClearPoint Neuro initiates limited market release of SmartFrame OR
- ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations
- ClearPoint congratulates partner PTC Therapeutics on completion of its BLA
